<DOC>
	<DOCNO>NCT03048136</DOCNO>
	<brief_summary>A Study Evaluate Safety Participants Chemotherapy-na√Øve Stage IV Recurrent Non-small Cell Lung Cancer Treated With Nivolumab Combination Ipilimumab</brief_summary>
	<brief_title>A Safety Study Nivolumab Combination With Ipilimumab Participants With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Stage IV recurrent nonSmall cell lung cancer Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Prior adjuvant neoadjuvant chemotherapy local , advanced disease allow complete least 6 month prior randomization Known epidermal growth factor receptor ( EGFR ) mutation anaplastic lymphoma syndrome ( ALK ) translocation sensitive target inhibitor therapy Active , know suspected autoimmune disease HIV infection Prior treatment drug target T cell costimulation pathway ( checkpoint inhibitor ) Untreated Central Nervous System metastases Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>